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Essentials
• Factor Xa inhibitors cause more abnormal menstrual bleeding (AUB) than vitamin-K antagonists (VKA).
• We analyzed data of AUB in women, evaluating dabigatran versus VKA.
• We observed a 41% lower risk of AUB in women on dabigatran compared to those on VKA.
• Our findings of lower AUB risk on dabigatran should be corroborated in future studies.
Summary. Introduction: Although direct oral anticoagulants (DOACs) are associated with a better safety profile than warfarin in patients with acute venous thromboembolism (VTE), direct factor Xa inhibitors involve a higher risk of abnormal uterine bleeding (AUB). We aimed to determine the risk of AUB during anticoagulation with dabigatran compared with warfarin. Methods: Post-hoc analysis of the pooled RE-COVER studies and the RE-MEDY trial. Incidences of AUB, based on a defined preferred terms search for adverse events, in female patients aged 18-50 years treated with dabigatran, were compared with those in women treated with warfarin. Results: Of the 2964 women included in the above-mentioned trials, 1280 women were in the relevant age category (18-50 years) and included in the current analysis. A total of 643 patients were randomized to treatment with dabigatran and 637 to treatment with warfarin. The overall rate of AUB was 8.1%, 5.9% for the women treated with dabigatran and 9.6% in those treated with warfarin, for an odds ratio for dabigatran-treated patients of 0.59 (95% confidence
Introduction
The preferred anticoagulant treatment for venous thromboembolism (VTE) has recently changed from low-molecular-weight heparin (LMWH) followed by vitamin-K antagonists (VKAs) to direct oral anticoagulants (DOACs) [1, 2] . The main reason for this change is the better safety and greater convenience of DOACs, with fixed doses and lack of a need for routine laboratory monitoring, over VKAs. For DOACs, lower risks of major bleeding, intracranial bleeding and fatal bleeding with at least a comparable efficacy in preventing recurrent VTE could be documented [3] . Notably, it has been shown that DOACs, in particular Xa inhibitors, are associated with a higher risk of abnormal uterine bleeding (AUB) in female VTE patients [4] [5] [6] [7] [8] [9] [10] [11] . Data on direct thrombin inhibitors have not been reported to date. With increasing use of DOACs in the treatment of acute VTE, more physicians are confronted with AUB in young female patients using DOACs. Further information on the use of individual DOACs and their association with menstrual bleeding patterns is thus most relevant for clinical practice. Therefore, we set out to perform an analysis of dabigatran use in female patients included in the phase 3 studies evaluating dabigatran vs. vitamin K antagonists. Our objective was to analyze abnormal uterine bleeding in patients using dabigatran or vitamin K antagonists in the setting of formal phase 3 clinical trials.
Methods

Patients
In this post hoc analysis we used data from the RE-COVER and RE-MEDY studies to compare the incidences of AUB in women randomized to dabigatran or warfarin for the treatment of VTE or prevention of recurrent VTE [12] [13] [14] . The study design, baseline population characteristics and results of the studies have been previously published [12] [13] [14] . Briefly, RE-COVER and RE-COVER II were identical randomized, double-blind, active-control, non-inferiority studies comparing dabigatran 150 mg b.i.d. and warfarin, targeted to an international normalized ratio (INR) of 2.0-3.0, in patients with VTE, who were followed for 6 months for the occurrence of recurrent VTE and major (MB) or clinically relevant non-major bleeding (CRNMB) complications [12, 13] . The RE-MEDY study was a randomized, double-blind, noninferiority study comparing dabigatran and warfarin for the extended treatment of VTE patients, who were followed for 6-36 months for the same endpoints as in the RE-COVER studies [14] .
Study objectives
The primary objective of the present study was to compare the occurrence of AUB in patients treated with dabigatran and warfarin. We conducted a defined preferred terms search (uterine hemorrhage or hematoma, polymenorrhagia, metrorrhagia, menorrhagia, menometrorrhagia or dysfunctional uterine bleeding) for adverse events, for all fertile female patients aged 18-50 years included in the three trials. Patients who rolled-over from RE-COVER to RE-MEDY and stayed on the same treatment were accounted for only once during the entire treatment period, whereas patients who switched treatment were analyzed as two different study subjects. Bleeding intensity was assessed and predefined as mild (awareness of sign(s) or symptom(s) that is/are easily tolerated), moderate (enough discomfort to cause interference with usual activity) and severe (incapacitating or causing inability to work or to perform usual activities) [12] [13] [14] . The secondary objective was to evaluate the management and decisions made when patients reported AUB and the effect of use of oral contraceptives on bleeding and recurrent VTE.
Statistics
To study between-group differences, we calculated odds ratios (ORs) and hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). All analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Cary, NC, USA).
Results and discussion
Of the 2964 women included in the above-mentioned trials, 1280 women were in the relevant age category. A total of 643 women had been randomized to treatment with dabigatran 150 mg twice daily and 637 to warfarin (Table 1 ). In the dabigatran-treated patients, three (0.5%) suffered MB vs. five (0.8%) in the warfarin-treated patients (HR, 0.65; 95% CI, 0.15-2.72). MB or NMCRB occurred in 30 (4.7%) patients randomized to receive dabigatran and 57 (8.9%) randomized to receive warfarin (HR, 0.53; 95% CI, 0.34-0.83). None of the bleeding events was fatal. AUB was reported by 99 women, of whom 38 (5.9%) were in the dabigatran and 61 (n = 9.6%) in the warfarin group (OR, 0.59; 95% CI, 0.39-0.90; P = 0.015). The median time to abnormal uterine bleeding was 110 days (25-75th percentile 32-186) for the dabigatrantreated patients and 78 days (25-75th percentile 30-131) for the warfarin-treated patients. The HR for AUB was 0.62 (95% CI, 0.41-0.93). Menorrhagia accounted for 69% and 90% of AUB events in the dabigatran and warfarin-treated patients, respectively, metrorrhagia for 24% and 8%. The majority of events were classified as mild in both the dabigatran (63%; n = 24) and the warfarin-treated group (56%; n = 34). Moderate events were reported in 25 patients (41%) in the warfarin group and 12 (31%) in the dabigatran group. In both groups, two severe AUB adverse events were reported. Although AUB was recorded as routine adverse event reporting in the study case report form, the intensity of the MB/CRNMB bleeding was prospectively assessed by the investigator and adjudicated. After matching the timing of reported AUBs to the adjudicated bleeding events, eight patients receiving dabigatran had a CRNMB event at the time of the abnormal uterine bleeding vs. 19 patients receiving warfarin. Finally, there were two patients receiving dabigatran who had AUB assessed as a major bleeding. The last INR measurement prior to the AUB in the patients randomized to warfarin treatment was between 2.0 and 3.0 in 49% of patients, below 2.0 in 27% and greater than 3.0 in 24%. The anticoagulant dose was temporarily reduced or discontinued in 18% of patients with AUB in the dabigatran group and 16% in the warfarin group. None of the latter suffered from recurrent VTE after this (temporary) change in anticoagulant therapy. Of all included patients, 270 used oral contraceptives at any time during the study (135 patients in each treatment group). Use of oral contraceptives at any time during the study was not associated with recurrent VTE (OR, 0.59; 95% CI, 0.20-1.72) nor with the occurrence of AUB (OR, 1.14; 95% CI, 0.70-1.86). These numbers were comparable for the comparisons within the two treatment arms.
The presented data indicate that dabigatran treatment had a significant 41% lower risk of AUB than warfarin among female VTE patients of fertile age (18-50 years) . No difference in AUB severity was noted between the treatment groups. Interestingly, most patients with AUB in the warfarin treatment cohort did not have supratherapeutic INR values. Also, use of oral contraceptives was not associated with recurrent VTE. This latter finding confirms previous studies and underlines the safety of continuing oral contraceptive treatment during anticoagulation therapy as an effective contraceptive method, as well as for prevention and treatment of menorrhagia. It has been shown that AUB occurs more often in women treated with rivaroxaban than those treated with warfarin (HR, 2.13; 95% CI, 1.57-2.89) [4] . On the other hand, in a post-hoc analysis of the AMPLIFY study, major vaginal bleeding events were very rare (< 0.1%) and nonmajor clinically relevant vaginal bleeding events occurred as frequently in patients treated with apixaban as those treated with warfarin (OR, 1.2; 95% CI, 0.67-2.0) [5] . Importantly, the definition of 'abnormal uterine bleeding' is any departure from normal menstruation or from a normal menstrual cycle pattern, considering key characteristics such as regularity, frequency, heaviness of flow and duration of flow, which has a significant impact on the patient's physical, social, emotional and material quality of life, and is associated with high healthcare costs [15] . Hence, major and non-major clinically relevant vaginal bleeding does not cover the whole range of AUB.
Observational studies support the observation that direct factor (F) Xa inhibitors, foremost rivaroxaban, are associated with a high prevalence of AUB, ranging from 20% to 73% [6] [7] [8] [9] [10] . The relevance of AUB in this specific patient category is underlined by the observation that AUB during the rivaroxaban treatment predisposed patients to recurrent VTE (OR, 5.3; 95% CI, 1.1-33), possibly to frequent temporarily dose reduction or anticoagulant cessation [7] . In our study, none of the 16-18% of patients suffering from AUB in whom the anticoagulation therapy was reduced or (temporarily) discontinued were diagnosed with recurrent VTE. Nonetheless, although specific guidelines are unavailable, experts agree on treating clinically relevant anticoagulation-associated AUB bleeding with tranexamic acid without changing anticoagulant therapy [11] .Obviously, this expert recommendation does not apply to the rare cases of major vaginal bleeding events.
One recent study suggests that warfarin suppresses thrombin generation more efficiently than dabigatran [16] . Because thrombin plays a key role locally in the uterus endometrium in the cessation of menstrual bleeding, the difference in suppression of thrombin generation may explain, although this is speculative, why dabigatran was associated with less AUB than warfarin [17, 18] Of note, differences in suppression of other hemostatic mechanisms by dabigatran vs. warfarin may further contribute to the observed differences in the occurrence of our primary endpoint [16] . The mechanism explaining a potentially different effect on menstrual bleeding of FXa inhibitors, notably rivaroxaban, and thrombin inhibitors remains unknown. In general, more attention needs to be given to menstrual bleeding in future VTE trials so that risk factors for AUB can be further determined and strategies to prevent or treat AUB can be validated.
Limitations of our study include a potential for underreporting because of the fact that AUB was not a predefined endpoint in the RE-COVER and RE-MEDY trials. Another limitation is the difference in definition of the endpoint of AUB across the trials with different DOACs, which limits cross-study comparison. Additionally, for this analysis, female patients between 18 and 50 years were included, which we think is a fair estimate of fertile age, although a history of hysterectomy was not collected. Finally, some patients from the RE-MEDY trial were rolled over from the RE-COVER trials, but they were only counted once if treatment was continued, whereas switchers were counted twice, for each treatment separately. Moreover, an analysis of bleeding rates stratified by time did not show a trend towards different risks over time (Table 2) . Head-to-head trials comparing risk of AUB during treatment with dabigatran vs. FXa inhibitors are necessary to further elucidate the potential relevance of our findings for daily clinical practice.
In conclusion, we observed a 41% lower risk of heavy menstrual bleeding in patients using dabigatran than warfarin for treatment of acute VTE within phase 3 trials. This observation warrants confirmation in future cohort studies in general practice.
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